U.S. Construction Stock News

What Tootsie Roll Industries’ Latest Earnings Reveal Tootsie Roll Industries (TR) reported second quarter and first half 2026 results on August 7, with stable revenue but lower net income and earnings per share compared with the same periods in 2025. For the second quarter, revenue was US$154.22 million compared with US$155.09 million a year earlier. Net income was US$13.35 million compared with US$17.54 million, and basic earnings per share from continuing operations was US$0.18 compared...

CoreWeave went into this print with a hot growth story and a stock that had already run hard. Then the earnings drop hit and the market punched the accelerator. The share price jumped about 19% to US$107.73, a sharp move for a company already priced on high expectations. The reason sits squarely in the top line and in operating leverage. Revenue for the quarter landed at US$2.6b and adjusted earnings before interest, tax, depreciation and amortisation margin reached 59%. For an AI...

Cooling inflation and a less aggressive Federal Reserve are quietly reshaping the backdrop for U.S. consumer discretionary and retail stocks. With headline CPI at 3.4% and core inflation at 2.5%, real purchasing power may be starting to breathe again, which could matter a lot for select retailers and brands. This article walks through three stocks exposed to this macro turn and why they might deserve a closer look right now. The stocks covered below are just a starting sample, and the full...

Belite Bio recently announced that the U.S. FDA has accepted and granted Priority Review to its New Drug Application for tinlarebant to treat Stargardt Disease Type 1, with a PDUFA target action date set for February 12, 2027. If approved, tinlarebant would become the first FDA‑approved treatment for this rare inherited retinal disease, highlighting Belite Bio’s potential role in addressing a significant unmet medical need. We will now examine how FDA Priority Review for tinlarebant, with a...

Nurix Therapeutics recently reported earning a US$10 million milestone payment from Sanofi for advancing its oral STAT6 degrader into a Phase 1 trial, while also enrolling the first patient in a global Phase 3 study of its BTK degrader bexobrutideg in partnership with Roche for relapsed or refractory CLL/SLL. Together, these updates highlight how Nurix’s DEL-AI protein degradation platform is now translating into late-stage clinical programs and tangible partnership revenues under its Sanofi...

Krystal Biotech earnings and revenue momentum come into focus Krystal Biotech (KRYS) is back in the spotlight after reporting second quarter 2026 results that included net income of US$54.77 million and basic earnings per share from continuing operations of US$1.85. See our latest analysis for Krystal Biotech. The recent earnings update and 24% net product revenue growth for VYJUVEK came after a strong run, with Krystal Biotech posting a year to date share price return of 34.81% and a 1 year...

DuPont de Nemours (NYSE: DD) has been selected to supply its MemCor membrane bioreactor system for the upgrade of the Lower Molonglo Water Quality Control Centre in Australia. The facility is the largest inland wastewater treatment plant in the country and is being upgraded to support population growth and more resilient water infrastructure. The project highlights DuPont's Water Solutions business and its role in advanced treatment technologies for global water infrastructure. This kind of...

In early August 2026, Netlist, Inc. announced it had entered into a five-year alliance with Samsung covering a patent portfolio cross-license, memory product supply, technology cooperation, and the settlement of all pending legal actions, with Samsung also agreeing to purchase 10 million Netlist shares. This agreement gives Samsung access to Netlist’s full server DIMM and High Bandwidth Memory patent portfolio while securing DRAM and NAND supply for Netlist, marking a material shift in...

Cooling inflation, softer rate expectations and cheaper fuel have shifted the ground for smaller U.S. consumer and travel stocks, but not all in the same way. Some companies may see a little more room on pricing and margins, while others could feel the pinch from still sticky shelter costs. This article walks through three stocks from a small-cap screener that appear positively exposed to this latest CPI backdrop. The stocks highlighted below are only a starting sample from this idea, and the...

Aquestive Therapeutics stock slipped about 4% today, even though the headline from Q2 is more about balance sheet breathing room than a collapse in the story. The company ended the quarter with US$98.5m in cash and reaffirmed full year 2026 guidance for revenue in the US$46m to US$50m range and a non GAAP adjusted EBITDA loss of US$35m to US$30m. For a small biopharma stock that trades on belief in future products, that mix of liquidity, steady guidance and ongoing losses is what is really...

IMAX stock has delivered a very strong 261.7% return over the past 5 years, yet the valuation checks send mixed signals as the Discounted Cash Flow (DCF) estimate points to meaningful upside while market multiples lean expensive. Over 5 years IMAX has returned 261.7%, which puts extra focus on whether recent gains are already pricing in much of the long term opportunity. The recent record IMAX performance for "Spider-Man: Brand New Day" in China can support expectations for premium format...

Why NuScale Power Stock Is Back in Focus After a Major Capital Raise NuScale Power (SMR) has moved back onto investors’ radar after the company filed for a US$750 million follow on equity offering of Class A common stock through an at the market program. See our latest analysis for NuScale Power. At around US$9.59 per share, NuScale Power has seen short term momentum pick up with a 30 day share price return of 14.85%. However, the share price is still down 41.20% year to date and the 1 year...

Viking Holdings has expanded its river cruise fleet, recently taking delivery of the 82-guest Viking Ptah in Cairo, purpose-built for Nile sailings on its 12-day Pharaohs & Pyramids itinerary. The Viking Ptah, mirroring the design of Viking’s European river fleet, underscores the company’s push to standardize guest experience while deepening its presence in Egypt’s high-end river cruise market. We’ll now examine how adding the Viking Ptah to Viking’s standardized river fleet could influence...

Comcast (CMCSA) is back in focus after Comcast Business and Colt Technology Services set up a joint global innovation lab to build programmable, API based connectivity for multinational enterprises across multiple regions. See our latest analysis for Comcast. Despite Comcast’s push into global Network as a Service partnerships and fresh network and media initiatives in recent months, the stock’s 30 day share price return of 6.26% contrasts with a year to date share price decline of 13.78% and...

CI&T stock barely flinched after Q2, slipping just 0.6% to US$3.62, even as the company posted another quarter of double digit organic revenue growth and lifted full year guidance. Short term traders saw a flat tape. Long term investors saw a business leaning harder into artificial intelligence deployment and value based contracts while accepting near term margin pressure. The real headline from this earnings set is the margin and profit squeeze. Adjusted EBITDA margin sat at 13.3% and...

Corsair Gaming recently reported second-quarter 2026 results, showing sales of US$314.34 million and a return to profitability with net income of US$8.84 million, and it also provided third-quarter revenue guidance of US$320 million to US$350 million. The company also raised its full-year 2026 net revenue outlook to a range of US$1.40 billion to US$1.47 billion, increasing the midpoint by about US$35 million compared with its prior guidance, which signals higher expectations for demand...

NeuroPace stock slipped about 3% to US$14.56 after its Q2 print, which may feel jarring given the company came into earnings with a modest gain over the past week but pressure over the past month. The headline is still about a business in loss making mode. Q1 basic earnings per share were a loss of US$0.20 on revenue of US$22.07m, and the trailing twelve months show US$99.53m in sales with ongoing losses. The real question now is how that loss profile fits against the multi year earnings and...

On 3 August 2026, Paychex, Inc. announced that its AI-powered workforce intelligence engine, WISE, is now integrated into Microsoft 365 Copilot and Teams, extending its human capital management capabilities directly into commonly used workplace tools across its platforms, including SurePayroll, Paychex Flex, and Paycor. This move marks an expansion of Paychex’s channel-agnostic ecosystem approach, embedding workforce insights and actions into partner workflows to reduce friction and support...

Sanara MedTech stock barely moved after the earnings release, slipping just 0.2% to about $34.30. For a company that has recently turned profitable and carries rich expectations, that is a surprisingly calm reaction. The headline is simple. The medical equipment business is now posting positive earnings from continuing operations over the last year while revenue sits above $100m on a trailing basis. The short term verdict from the market is muted. The real question is whether that new...

Cullen/Frost Bankers, Inc. recently reported past second-quarter 2026 results showing higher net interest income of US$447.73 million and net income of US$172.06 million year over year, alongside reduced net charge-offs and the completion of a US$160.03 million share repurchase program covering 1.85% of its stock. The company also raised and narrowed its full-year 2026 net interest income and margin guidance while affirming common and preferred dividends, signaling management confidence in...

Why Teradata Stock Is Back In Focus After Its AI And Earnings Update Teradata (TDC) is back on investors’ radar after outlining its Teradata 3.0 AI plan, launching its Autonomous Knowledge Platform and related tools, and raising full year earnings guidance alongside stronger recent financial results. See our latest analysis for Teradata. At a share price of US$26.74, Teradata has seen short term share price weakness, with the 30 day share price return down 21.26% and the 90 day share price...

CCC Intelligent Solutions Holdings (CCC) stock is back in focus after the company released second quarter 2026 results alongside fresh revenue guidance for the third quarter and full year. See our latest analysis for CCC Intelligent Solutions Holdings. CCC Intelligent Solutions Holdings shares have picked up momentum around the latest earnings and guidance, with a 30-day share price return of 11.88% and a 90-day share price return of 64.39%, although the 1-year total shareholder return is...

Wells Fargo (WFC) has been active in the debt markets, announcing new preferred depositary shares and multiple senior unsecured note offerings across different maturities. These moves give stock investors fresh information on the bank’s funding mix. See our latest analysis for Wells Fargo. The recent funding activity comes after a strong run in Wells Fargo’s stock, with a 90 day share price return of 20.52% and a 1 year total shareholder return of 16.66%. However, the year to date share price...

DexCom (DXCM) is back in focus after its latest quarterly update, which combined higher second quarter revenue and net income with a raised full year sales outlook and confirmation of a completed share repurchase program. See our latest analysis for DexCom. The latest earnings release and higher full year revenue guidance have coincided with a strong upswing in DexCom's share price, including a 57.04% 90 day share price return and 36.46% year to date share price return, while the 3 year total...